XOMA (NASDAQ:XOMA - Get Free Report) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating in a research report issued on Thursday.
Separately, HC Wainwright reiterated a "buy" rating and set a $104.00 target price on shares of XOMA in a research note on Friday, March 28th.
Read Our Latest Stock Analysis on XOMA
XOMA Stock Performance
NASDAQ XOMA traded down $0.06 on Thursday, hitting $19.17. 7,965 shares of the stock were exchanged, compared to its average volume of 27,259. The company has a market capitalization of $229.63 million, a PE ratio of -5.46 and a beta of 1.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. The business's fifty day moving average is $22.92 and its 200 day moving average is $26.51. XOMA has a 52 week low of $18.35 and a 52 week high of $35.00.
XOMA (NASDAQ:XOMA - Get Free Report) last issued its earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.17). XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The firm had revenue of $8.70 million during the quarter, compared to the consensus estimate of $8.75 million. Research analysts anticipate that XOMA will post -1.41 EPS for the current fiscal year.
Insider Buying and Selling
In other XOMA news, CIO Bradley Sitko bought 4,134 shares of XOMA stock in a transaction dated Friday, March 21st. The stock was bought at an average price of $23.89 per share, with a total value of $98,761.26. Following the completion of the transaction, the executive now owns 10,484 shares in the company, valued at $250,462.76. The trade was a 65.10 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the company's stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $26.10, for a total transaction of $13,069,366.20. The disclosure for this sale can be found here. In the last 90 days, insiders purchased 27,625 shares of company stock valued at $693,674. Company insiders own 7.20% of the company's stock.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the business. Woodline Partners LP lifted its holdings in shares of XOMA by 63.9% during the 4th quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company's stock worth $4,107,000 after acquiring an additional 60,927 shares during the period. JPMorgan Chase & Co. lifted its stake in XOMA by 238.9% during the fourth quarter. JPMorgan Chase & Co. now owns 12,089 shares of the biotechnology company's stock worth $318,000 after purchasing an additional 8,522 shares during the last quarter. Barclays PLC boosted its holdings in shares of XOMA by 300.7% in the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company's stock valued at $298,000 after purchasing an additional 8,447 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of XOMA in the 4th quarter valued at $206,000. Finally, Renaissance Technologies LLC increased its stake in shares of XOMA by 89.8% in the 4th quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company's stock valued at $423,000 after purchasing an additional 7,619 shares during the last quarter. 95.92% of the stock is owned by institutional investors.
About XOMA
(
Get Free Report)
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
Featured Stories
Before you consider XOMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XOMA wasn't on the list.
While XOMA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
